ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $1.15M

      Shares

      15.5k

      % of Portfolio

      0.00%

      Average Buy Price

      $44.5

      Avg closing price
      Price range

      1 Polen Capital Mirum Pharmaceuticals Trades

      Polen Capital acquired 15.5k Mirum Pharmaceuticals shares worth $1.15M. That's 0.00% of their equity portfolio (133rd largest holding). The stake costed the investor $691k, netting the investor a gain of 67% so far.

      Avg closing price
      Price range
      New holding (+15.5k shares) Q2 2025
      Avg closing price $44.54
      Price range $38.39 - $51.11

      News about Mirum Pharmaceuticals Inc and Polen Capital

      Silverarc Capital Management LLC Acquires 436 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

      Silverarc Capital Management LLC Acquires 436 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

      ¡­ Selling at Mirum Pharmaceuticals In other Mirum Pharmaceuticals news, SVP Jolanda ¡­ on Mirum Pharmaceuticals About Mirum Pharmaceuticals (Free Report) Miru...

      EIN News Pharmaceuticals EIN News Pharmaceuticals, over 1 year ago
      Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed

      Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed

      Benzinga Pro data, Mirum Pharmaceuticals (NASDAQ: MIRM ) reported Q4 sales of $27.91 million. Earnings fell to a loss of $36.43 million, resulting in a 2.03%...

      Benzinga Benzinga, over 2 years ago
      AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday

      AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday

      Keybanc boosted Five Below, Inc. (NASDAQ: FIVE ) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock....

      Benzinga Benzinga, over 2 years ago
      Looking Into Mirum Pharmaceuticals''s Return On Capital Employed

      Looking Into Mirum Pharmaceuticals''s Return On Capital Employed

      According to Benzinga Pro data, during Q2, Mirum Pharmaceuticals (NASDAQ: MIRM ) posted sales of $17.48 million. Earnings were up 26.45%, but Mirum Pharmaceu...

      Benzinga Benzinga, about 3 years ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×